

Application No. 09/926,218

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Arne HOLMGREN et al.

Group Art Unit : 1621

Appl. No : 09/926,218  
(National Stage of PCT/JP00/02076)

Examiner : Kumar

I.A. Filed : March 31, 2000

For : SUBSTRATE FOR THIOREDOXIN REDUCTASE

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir :

Further to the previously filed Information Disclosure Statements, Applicants hereby bring the following information to the attention of the Examiner.

Holmgren A., Thioredoxin, Ann. Rev. Biochem., 54:237-271, 1985

Schewe, T., Gen. Pharmacol. 26, Vol. 26, No. 6, 1153-1169, 1995

A lecture by Arne Holmgren at a conference at the Pasteur Institute disclosing the results that mammalian thioredoxin reductase was a selenoprotein with a selenocysteine residue in the active site, which was later published in Oxidative Stress, in Cancer, AIDS and Neurodegenerative Diseases (Montagnier, Olivier, Pasquier, Eds.) Marcel Dekker, Inc., New York, pp 229-246, 1998, "23 Redox Regulation by the Thioredoxin and Glutaredoxin Systems", Holmgren et al.

12/01/2006 JADD01 00000015 09926218

02 FC:1006

100.00 09

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these

P21480.A21


Application No. 09/926,218

documents, and to make them of record in this application by initialing in the appropriate spaces on the Form-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants enclose \$180.00 in payment of the fee for consideration of this Information Disclosure Statement. If any fee is needed for consideration of the this paper and the information cited therein, authorization is hereby provided to charge any required fee, including any fee under 37 C.F.R. 1.17(p), to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted,  
Arne HOLMGREN et al.




Bruce H. Bernstein  
Reg. No. 29,027

November 30, 2006  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Arnold Turk  
Reg. No. 33094

FORM PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P21480	Application No. 09/926,218
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Arne HOLMGREN et al.	
		Filing Date I.A. Filed March 31, 2000	Group 1621



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
1	Holmgren A., Thioredoxin, Ann. Rev. Biochem., 54:237-271, 1985.
2	Schewe, T., Gen. Pharmacol. 26, Vol. 26, No. 6, 1153-1169, 1995.
3	A lecture by Arne Holmgren at a conference at the Pasteur Institute disclosing the results that mammalian thioredoxin reductase was a selenoprotein with a selenocysteine residue in the active site, which was later published in Oxidative Stress, in Cancer, AIDS and Neurodegenerative Diseases (Montagnier, Olivier, Pasquier, Eds.) Marcel Dekker, Inc., New York, pp 229-246, 1998, "23 Redox Regulation by the Thioredoxin and Glutaredoxin Systems", Holmgren et al..

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.